mTOR in squamous cell carcinoma of the oesophagus: A potential target for molecular therapy?

Journal of Clinical Pathology

Volumn 61, Issue 8, 2008, Pages 909-913

  Boone, J ^a   Ten Kate, F J W ^a   Offerhaus, G J A ^a   Van Diest, P J ^a   Borel Rinkes, I H M ^a   Van Hillegersberg, Richard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PARAFFIN; RAPAMYCIN; SERINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TISSUE FIXATION; TISSUE MICROARRAY; VALIDATION PROCESS;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROTEIN KINASES; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL;

EID: 49149112670     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2008.055772     Document Type: Article

References (41)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006:24:2137-50.
2. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007;8:545-53.
3. Alexiou C, Khan OA, Black E, et al. Survival after esophageal resection for carcinoma: the importance of the histologic cell type. Ann Thorac Surg 2006;82:1073-7.
4. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9.
5. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34.
6. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005;10:590-601.
7. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005;56:47-60.
8. Sandsmark DK, Pelletier C, Weber JD, et al. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol 2007;22:895-903.
9. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005;16:29-37.
10. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006;66:1203-12.
11. Bose S, Chandran S, Mirocha JM, et al. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006;19:238-45.
12. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67.
13. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004;10:6779-88.
14. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46.
15. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
16. Liu Y, Hidayat S, Su WH, et al. Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade. Cell Biochem Funct 2007;25:45-53.
17. Nathan CA, Amirghahari N, Abreo F, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2004;10:5820-7.
18. Hou G, Xue L, Lu Z, et al. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 2007;253:236-48.
19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
20. Simon R, Sauter G. Tissue microarray (TMA) applications: implications for molecular medicine. Expert Rev Mol Med 2003;5:1-12.
21. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. BMJ 2002;325:648-51.
22. Gabbert HE. Squamous cell carcinoma of the esophagus. In: Hamilton SR, Aaltonen LA, eds. WHO classification of tumours - pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press, 2000:10-6.
23. Wittekind C, Greene FL, Hutter RVP, et al. TNM atlas. Illustrated guide to the TNM/pTNM classification of malignant tumors. Berlin: Springer-Verlag, 2004.
24. Boone J, van Hillegersberg R, van Diest PJ, et al. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Archiv. Published Online First: 8 April 2008. doi:10.1007/s00428-008-0602-0.
25. Lin HJ, Hsieh FC, Song H, et al. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 2005;93:1372-81.
26. Herberger B, Puhalla H, Lehnert M, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007;13:4795-9.
27. Xu M, Jin YL, Fu J, et al. The abnormal expression of retinoic acid receptor-beta, p53 and Ki67 protein in normal, premalignant and malignant esophageal tissues. World J Gastroenterol 2002;8:200-2.
28. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007;17:666-81.
29. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22.
30. Cen L, Arnoczky KJ, Hsieh FC, et al. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 2007;20:936-46.
31. Lin F, Zhang PL, Yang XJ, et al. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006;36:283-93.
32. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-73.
33. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-5.
34. Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007;120:1803-10.
35. Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007;83:425-32.
36. Noh WC, Kim YH, Kim MS, et al. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat. Published Online First: 6 September 2007. doi:10.1007/s10549-007-9746-x.
37. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006;17:487-94.
38. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 2002;12:60-6.
39. Adams PD, Kaelin Jr WG. Negative control elements of the cell cycle in human tumors. Curr Opin Cell Biol 1998;10:791-7.
40. Stewart CL, Soria AM, Hamel PA. Integration of the pRB and p53 cell cycle control pathways. J Neurooncol 2001;51:183-204.
41. Kawakubo H, Ozawa S, Ando N, et al. Alterations of p53, cyclin D1 and pRB expression in the carcinogenesis of esophageal squamous cell carcinoma. Oncol Rep 2005;14:1453-9.